News

Elestrin (estradiol gel 0.06%) was approved for this application by the FDA in December 2006. Bradley in-licensed Elestrin, which is patent protected until 2022, from BioSante Pharmaceuticals in

Astion Pharma recently completed a phase I development program for the drug, ASF-1096, for the treatment of the serious skin disease, cutaneous lupus erythematosus. The results from the

UK-based Chroma said that it will shortly start its second phase II trial, in non-small cell lung cancer (NSCLC). This follows the recent initiation of a phase II

Professor Josef Smolen, Division of Rheumatology at the Medical University of Vienna, Austria and colleagues did a comprehensive study of the three new drugs – rituximab, abatacept and

The UK accountants predict that by 2020 the global pharmaceutical market will more than double in value to $1.3 trillion, driven by soaring worldwide demand for medicines and

Nalbuphine ER, designed to be taken as a twice-daily tablet, uses Penwest’s drug delivery technology. The main objective of this phase IIa study is to evaluate the analgesic

The trial was designed to study the interaction between valopicitabine, Idenix’s lead drug candidate for the treatment of hepatitis C, pegylated interferon and ribavirin compared to pegylated interferon

The final purchase price is $12.5 million less than the originally negotiated and announced purchase price due to the termination of Alliant’s agreement with Morton Grove Pharmaceuticals to

In a press release regarding the agreement, Immtech said that the companies may also collaborate on efforts to develop pafuramidine as a preventative therapy for patients at risk